Skip to main content

Table 2. PCR-unadjusted treatment response of study patients treated with artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL)

From: Therapeutic efficacy of artesunate-amodiaquine and artemether-lumefantrine and polymorphism in Plasmodium falciparum kelch13-propeller gene in Equatorial Guinea

PCR-unadjusted
Treatment responses
Artesunate-amodiaquine Artemether-lumefantrine
Malabo (N = 88)
n (%)
Bata (N = 88)
n (%)
Ebibeyin (N = 88)
n (%)
Malabo (N = 50)
n (%)
Bata (N = 88)
n (%)
Ebibeyin (N = 88)
n (%)
LCF 0 1 (1.2) 2 (2.5) 0 0 0
LPF 0 2 (2.5) 7 (8.8) 3 (7.1) 4 (4.7) 22 (26.5)
ACPR 67 (100) 78 (96.3) 71 (88.8) 39 (92.9) 81 (95.3) 61 (73.5)
Total per-protocol 67 81 80 42 85 83
Lost follow-up/withdrawn 21 (23.9) 7 (8) 8 (9.1) 8 (16) 3 (3.4) 5 (5.7)
Kaplan Meier: cure rate 67 (100) 78 (96.3) 71 (88.8) 39 (92.9) 81 (95.3) 61 (73.5)
  1. LCF: late clinical failure; LPF: late parasitological failure; ACPR: adequate clinical and parasitological response